The vector of anti-G250 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human G250. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-G250 antibody linked to CD3-zeta signaling domains. And the vector product was designed for modifying T lymphocytes, and the modified T lymphocytes was designed for renal carcinoma treatment.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
|CAR-MZ201||Anti-CAIX (G36) h(CD3ζ) CAR, pCDCAR1|
|VP-CAR-LC891||Lenti-Carbonic anhydrase IX (CA9) CAR (scFv-CD28-CD3ζ, G36) Viral Particle|
|CAR-T-2-L404-4G||G250 h(CD4-FcεRIγ) CAR, [T]|
|CAR-T-2-M305-2G||Anti-CAIX scFv h(CD28-FcεRIγ) CART, pCDCAR1|
|CAR-T-2-L404-2G||G250 h(CD28-FcεRIγ) CAR, [T]|
|CAR-T-2-L404-2Z||G250 h(CD28-CD3ζ) CAR, [T]|
|CAR-T-3-L404-2BZ||G250 h(CD28-41BB-CD3ζ) CAR, [T]|
|CAR-T-3-M305-2BZ||Anti-CAIX scFv h(CD28-41BB-CD3ζ) CART, pCDCAR1|
|CAR-T-1-L404-2||G250 h(CD28) CAR, [T]|
|VP-CAR-LC56||Lenti-CAIX CAR (scFv-CD8-CD3ζ, G250) Viral Particle|
Copyright © 2007 - 2018 Creative Biolabs. All Rights Reserved